NZ776102A - Macrocyclic compound and use thereof - Google Patents

Macrocyclic compound and use thereof

Info

Publication number
NZ776102A
NZ776102A NZ776102A NZ77610219A NZ776102A NZ 776102 A NZ776102 A NZ 776102A NZ 776102 A NZ776102 A NZ 776102A NZ 77610219 A NZ77610219 A NZ 77610219A NZ 776102 A NZ776102 A NZ 776102A
Authority
NZ
New Zealand
Prior art keywords
disease
kidney
mitochondrial
inflammatory
formula
Prior art date
Application number
NZ776102A
Other languages
English (en)
Inventor
Tsuyoshi Maekawa
Hideto Fukushi
Ryoma Hara
Minoru Ikoma
Toshitake Kobayashi
Shigemitsu Matsumoto
Ayumu Niida
Naoyoshi Noguchi
Satoshi Sasaki
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70975488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ776102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of NZ776102A publication Critical patent/NZ776102A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ776102A 2018-12-05 2019-12-04 Macrocyclic compound and use thereof NZ776102A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
NZ776102A true NZ776102A (en) 2024-12-20

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ776102A NZ776102A (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Country Status (18)

Country Link
US (1) US11518763B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890738A4 (cg-RX-API-DMAC7.html)
JP (2) JP7895177B2 (cg-RX-API-DMAC7.html)
KR (1) KR102919982B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164468A (cg-RX-API-DMAC7.html)
AR (1) AR117251A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391942B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010704A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121952C (cg-RX-API-DMAC7.html)
CL (1) CL2021001451A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007304A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006527A (cg-RX-API-DMAC7.html)
NZ (1) NZ776102A (cg-RX-API-DMAC7.html)
PH (1) PH12021551262A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105125XA (cg-RX-API-DMAC7.html)
TW (1) TWI820266B (cg-RX-API-DMAC7.html)
UA (1) UA127872C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020116660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
BR112023004567A2 (pt) * 2020-09-14 2023-04-04 Sanofi Sa Derivados de tetrahidroisoquinolina para o tratamento de doenças do sangue e doenças inflamatórias
AU2024251986A1 (en) * 2023-04-03 2025-10-16 Acelink Therapeutics, Inc. Novel compounds and uses thereof
CN119707895B (zh) * 2023-12-18 2026-03-31 江苏苏中药业研究院有限公司 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法
WO2026026967A1 (zh) * 2024-08-02 2026-02-05 劲方医药科技(上海)股份有限公司 丙烯酰基类化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
WO2017026516A1 (ja) 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
EP3573963B1 (en) 2017-01-30 2021-09-01 Biogen MA Inc. Nrf2 activator
US20190389836A1 (en) * 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
MX2021006527A (es) 2021-07-21
TWI820266B (zh) 2023-11-01
UA127872C2 (uk) 2024-01-31
KR20210099622A (ko) 2021-08-12
EP3890738A1 (en) 2021-10-13
WO2020116660A1 (en) 2020-06-11
SG11202105125XA (en) 2021-06-29
JP7895177B2 (ja) 2026-07-27
CA3121952A1 (en) 2020-06-11
CO2021007304A2 (es) 2021-06-21
AR117251A1 (es) 2021-07-21
US11518763B2 (en) 2022-12-06
JP2024123202A (ja) 2024-09-10
EP3890738A4 (en) 2022-08-17
CN113164468A (zh) 2021-07-23
TW202039494A (zh) 2020-11-01
BR112021010704A2 (pt) 2021-08-24
CL2021001451A1 (es) 2021-12-24
PH12021551262A1 (en) 2021-10-25
US20220119391A1 (en) 2022-04-21
AU2019391942B2 (en) 2024-03-21
KR102919982B1 (ko) 2026-02-02
AU2019391942A1 (en) 2021-06-03
CA3121952C (en) 2025-05-13
JP2022510736A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
PH12021551262A1 (en) Macrocyclic compound and use thereof
Mishra et al. Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets
MX2015001115A (es) Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal.
CR20210085A (es) Compuestos de 2,6-diaminopiridina
NZ720660A (en) Apoptosis signal-regulating kinase inhibitors
MX2012015105A (es) Inhibidores de cinasa de regulacion mediante señal de apoptosis.
PH12018500261B1 (en) Azole benzene derivative
JOP20210329A1 (ar) مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز
MX361925B (es) Medicamento inhalable que comprende tiotropio.
PH12013502152B1 (en) Administration of iloprost as aerosol bolus
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112018068996A2 (pt) derivados de triterpeno, compostos intermediários e composições farmacêuticas
UY32414A (es) Nuevos metodos
PH12015500418A1 (en) Pyridine derivative and medicine
PH12015502264A1 (en) Pyrazole derivative
IN2014DN00185A (cg-RX-API-DMAC7.html)
MX2014005165A (es) Proceso novedoso para la preparacion de acilguanidinas y aciltioureas.
Hansbro et al. A short-term model of COPD identifies a role for mast cell tryptase
Althaqfi et al. Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period
Cozza et al. 6-minute walking test (6MWT) in patients with silicosis
Milger et al. Acute vasoreactivity testing with sildenafil vs nitric oxide in patients with PAH
Levina et al. Risk factors of development of endothelium dysfunctions at smokers
Paralija et al. Clinical features of pulmonary tuberculosis in patients with diabetes mellitus
Bouyssou et al. Late asthmatic response is modulated by TRPA1 antagonists in ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs
UA86393U (ru) Способ диагностики степени систолической сердечной недостаточности левого желудочка при сердечно-сосудистых заболеваниях

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251031